Name: UMIN ID:
Unique ID issued by UMIN | UMIN000004010 |
---|---|
Receipt number | R000004821 |
Scientific Title | Efficacy and safety of combination therapy with vildagliptin and nateglinide in type 2 diabetes. |
Date of disclosure of the study information | 2010/09/30 |
Last modified on | 2013/06/19 11:51:03 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2010/08/06 17:54:48 | ||
2 | Update | 2010/09/10 11:44:32 | Public title Public title Acronym Acronym |
|
3 | Update | 2010/09/10 11:47:28 | Narrative objectives1 Narrative objectives1 Primary outcomes Primary outcomes |
|
4 | Update | 2010/09/10 11:48:56 | Interventions/Control_1 Interventions/Control_1 Interventions/Control_2 Interventions/Control_2 |
|
5 | Update | 2010/09/10 11:50:21 | Organization Organization |
|
6 | Update | 2010/09/10 11:51:07 | Date of protocol fixation Anticipated trial start date |
|
7 | Update | 2010/09/10 12:05:05 | Key exclusion criteria |
|
8 | Update | 2010/10/07 17:57:14 | Organization Organization Category of Funding Organization |
|
9 | Update | 2010/10/08 10:21:06 | Primary outcomes Primary outcomes Key secondary outcomes Key secondary outcomes |
|
10 | Update | 2011/02/07 16:26:14 | Recruitment status Anticipated trial start date |
|
11 | Update | 2011/03/07 11:02:53 | Last follow-up date |
|
12 | Update | 2011/03/07 11:04:47 | Email1 |
|
13 | Update | 2011/06/25 21:58:35 | Organization Organization Post marketing survey by drug manufacture etc., specified by Japanese law. |
|
14 | Update | 2011/06/25 21:59:06 | Recruitment status |
|
15 | Update | 2012/06/02 12:05:10 | Recruitment status |
|
16 | Update | 2013/06/19 11:51:03 | Key inclusion criteria Key inclusion criteria Key exclusion criteria Key exclusion criteria |